Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ANIP stock, giving a Buy rating on April 22.
Faisal Khurshid has given his Buy rating due to a combination of factors including ANI Pharmaceuticals’ potential financial benefits from their involvement with cretostimogene, a promising product in bladder cancer treatment. ANIP is currently in litigation over its rights to a 5% royalty from the worldwide net sales of cretostimogene, which could be a significant revenue stream if the litigation is resolved in their favor.
Additionally, ANIP’s strategic shift from a traditional generics manufacturer to a hybrid model that includes branded rare disease drugs positions it well for future growth. The company’s unique US-based manufacturing capabilities for generics and its commercial growth in branded products further support the positive outlook. Khurshid believes that the market may be underestimating these factors, making ANIP a solid investment opportunity in the current market conditions.
Khurshid covers the Healthcare sector, focusing on stocks such as Pliant Therapeutics, aTyr Pharma, and Kymera Therapeutics. According to TipRanks, Khurshid has an average return of 26.3% and a 45.59% success rate on recommended stocks.
In another report released on April 22, Piper Sandler also reiterated a Buy rating on the stock with a $79.00 price target.